Cyntegrity Expands Operations into the USA

David J. Lacagnina appointed Chief Business Officer

Frankfurt, Dec. 1, 2019 – Cyntegrity, an industry leader in intelligent Risk-Based Quality Management (RBQM) solutions for clinical trials, today announced its expansion into the USA with the appointment of David Lacagnina to its senior management team.

“I want to welcome David to our continuously growing team of talented RBQM experts. Based in our US offices, David will assume the role of Chief Business Officer, as we continue our impressive global growth throughout North America, Europe, and the Asia Pacific,” said Artem Andrianov, Founder and Chief Executive Officer.

Before joining Cyntegrity, David held leadership positions at endpoint, Comprehend Systems, Pharmasol, and ThoughtSphere, helping guide these companies through their early stages of business and corporate development to establish themselves as premier technology providers. David also serves on the Board of Advisors at Strategikon Pharma, Inc.

“The Cyntegrity MyRBQM platform is a highly differentiated technology for holistic Risk-Based Quality Management that will greatly benefit sponsors and CROs alike. With the revised ICH guidelines, I believe now is the time to significantly increase the company’s growth in this area,” said David.

About Cyntegrity – Developed with input from the FDA, EMA, and ICH E6 (R2), the MyRBQM platform is deployed to over 190 companies worldwide to support Centralized Statistical Monitoring, Medical Review, Quality Risk Management in over 500 Clinical Trials.

MyRBQM has a library of comprehensive statistical algorithms to determine the quality, accuracy, and integrity of clinical trial data both during and after the clinical trial. The result will increase operational efficiency, and lower costs, as sponsors and CROs shift to Risk-Based Quality Management of Clinical Trials.